Search results
Results from the WOW.Com Content Network
570 Acute and subacute necrosis of liver. 570.0 Hepatic failure, acute; 571 Chronic liver disease and cirrhosis. 571.0 Fatty liver, alcoholic; 571.2 Cirrhosis, liver, alcoholic; 571.4 Hepatitis, chronic, unspec. 571.5 Cirrhosis, NOS; 571.6 Primary biliary cirrhosis; 571.9 Liver disease, chronic, unspec. 572 Liver abscess and sequelae of chronic ...
Liver function tests (LFTs or LFs), also referred to as a hepatic panel or liver panel, are groups of blood tests that provide information about the state of a patient's liver. [1] These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin , bilirubin (direct and indirect), and others.
Liver failure is the inability of the liver to perform its normal synthetic and metabolic functions as part of normal physiology. Two forms are recognised, acute and chronic (cirrhosis). [ 1 ] Recently, a third form of liver failure known as acute-on-chronic liver failure ( ACLF ) is increasingly being recognized.
Phrases subfulminant hepatic failure and late onset hepatic failure were coined for onset between 2 weeks to 3 months and for 8 weeks to 24 weeks, respectively. [ 42 ] [ 43 ] The umbrella phrase of acute liver failure was proposed by King's College group, which has been adopted in this article.
Liver showing chronic passive congestion associated with tricuspid valve incompetence. So called 'nutmeg liver', Split nutmeg, for those who have never seen this appearance. Close up of congested liver showing the 'nutmeg' appearance. Congestive hepatopathy, is liver dysfunction due to venous congestion, usually due to congestive heart failure.
The comprehensive metabolic panel, or chemical screen (CMP; CPT code 80053), is a panel of 14 blood tests that serves as an initial broad medical screening tool. The CMP provides a rough check of kidney function, liver function, diabetic and parathyroid status, and electrolyte and fluid balance, but this type of screening has its limitations.
A liver support system or diachysis is a type of therapeutic device to assist in performing the functions of the liver. Such systems focus either on removing the accumulating toxins (liver dialysis), or providing additional replacement of the metabolic functions of the liver through the inclusion of hepatocytes to the device (bioartificial liver device).
The surgeon and portal hypertension expert Charles Gardner Child (1908–1991) (with Turcotte) of the University of Michigan first proposed the scoring system in 1964 in a textbook on liver disease. [3] It was modified by Pugh et al. in 1972 in a report on surgical treatment of bleeding from esophageal varices. [4]